Global Insulin Like Growth Factor II Market Size By Type (Dusigitumab, M-630), By Application (Breast Cancer, Hormone Sensitive Breast Cancer), By Region, And Segment Forecasts, 2023 to 2032

The Global Insulin-Like Growth Factor II (IGF-II) Market was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.3 billion by 2031, expanding at a CAGR of 8.4% during the forecast period (2023–2031). IGF-II, a critical polypeptide hormone involved in growth and development, has garnered significant interest in the biomedical and pharmaceutical sectors. Its growing role in metabolic regulation, cancer research, regenerative medicine, and neurodegenerative disease treatment is propelling demand. Advancements in molecular biology and a deeper understanding of IGF pathways have enhanced therapeutic applications and diagnostic relevance, fueling market growth.

Drivers:

1. Rising Incidence of Cancer and Metabolic Disorders:

The increasing prevalence of cancer, diabetes, and growth disorders globally is boosting research into IGF-II, given its key role in cellular proliferation and metabolism.

2. Expanding Applications in Regenerative Medicine:

IGF-II’s influence on muscle repair, neurogenesis, and wound healing is making it a valuable molecule in tissue engineering and regenerative therapies.

3. Advances in Biotechnology and Targeted Therapies:

Technological breakthroughs in gene expression profiling and targeted drug development are supporting the clinical utility of IGF-II as a biomarker and therapeutic target.

Restraints:

1. Regulatory and Ethical Challenges:

The development and commercialization of IGF-II-based therapies face stringent regulatory requirements, limiting faster market adoption, especially in regions with complex approval pathways.

2. High Research and Production Costs:

The cost-intensive nature of protein research, purification, and production acts as a barrier for small biotech firms, restraining broader market participation.

Opportunity:

1. Precision Medicine and Personalized Therapies:

The growing trend of individualized treatment protocols provides a significant opportunity for IGF-II, particularly in cancer genomics and metabolic disease profiling.

2. Untapped Potential in Emerging Markets:

Countries in Asia-Pacific and Latin America offer robust growth potential due to increasing investments in healthcare infrastructure and a rising burden of chronic illnesses.

Market by System Type Insights:

By system type, the Recombinant IGF-II segment dominated the market in 2023, owing to its increasing use in research and clinical trials. Recombinant variants enable large-scale production with high purity, making them ideal for therapeutic and diagnostic applications. Meanwhile, Natural IGF-II Extracts are gaining traction for nutraceutical and wellness-based products.

Market by End-use Insights:

The Pharmaceutical & Biotechnology Companies segment held the largest revenue share in 2023, driven by the high volume of clinical research activities and drug development pipelines targeting IGF pathways. The Academic & Research Institutes segment is also expanding, supported by government-funded projects on genetic diseases and neurodegenerative disorders.

Market by Regional Insights:

North America led the global IGF-II market in 2023, benefiting from a well-established biotech sector, robust R&D funding, and a high prevalence of target diseases. However, Asia-Pacific is projected to witness the fastest CAGR through 2031, fueled by expanding healthcare systems, increasing academic collaboration, and rising pharmaceutical investments in countries like China, India, and South Korea.

Competitive Scenario:

Key players in the Global Insulin-Like Growth Factor II Market include:

Abcam plc

Thermo Fisher Scientific Inc.

Merck KGaA

PeproTech (part of Thermo Fisher)

Bio-Techne Corporation

Cell Signaling Technology

R&D Systems

RayBiotech, Inc.

These companies are focusing on expanding their product portfolios with high-purity recombinant proteins, entering strategic collaborations, and investing in preclinical research and commercialization partnerships.

Scope of Work – Global Insulin-Like Growth Factor II Market

Report Metric Details

Market Size (2023) USD 1.2 billion

Projected Market Size (2031) USD 2.3 billion

CAGR (2023–2031) 8.4%

Market Segments System Type (Recombinant IGF-II, Natural Extracts), End-use (Pharma & Biotech Companies, Research Institutes), Region

Growth Drivers Rising prevalence of cancer & metabolic disorders, regenerative medicine applications, biotechnology advancements

Opportunities Personalized therapies, expansion in emerging markets

Key Market Developments:

2023: Thermo Fisher Scientific launched a new range of high-purity recombinant IGF-II proteins for cell culture and therapeutic research applications.

2024: Bio-Techne collaborated with a European cancer research consortium to develop IGF-II-based diagnostic assays for early tumorigenesis.

2025: Abcam expanded its protein research division with a focus on IGF-related signaling pathway analysis, supporting precision oncology research.

FAQs:

1. What is the current market size of the Global Insulin-Like Growth Factor II Market?

The market was valued at USD 1.2 billion in 2023.

2. What is the major growth driver of the Global Insulin-Like Growth Factor II Market?

The major growth driver is the rising prevalence of cancer and metabolic disorders, which necessitate IGF-II-based diagnostics and therapeutics.

3. Which is the largest region during the forecast period in the Global Insulin-Like Growth Factor II Market?

North America holds the largest share, while Asia-Pacific is expected to witness the fastest growth.

4. Which segment accounted for the largest market share in the Global Insulin-Like Growth Factor II Market?

The Recombinant IGF-II segment dominated the market in 2023.

5. Who are the key market players in the Global Insulin-Like Growth Factor II Market?

Key players include Thermo Fisher Scientific, Abcam plc, Merck KGaA, PeproTech, and Bio-Techne Corporation.